Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Canuck Dave who wrote (26404)	1/24/2000 9:10:00 PM
From: JayLuv	Read Replies (1) \| Respond to of 56535

CRA license SMDX genome patent SMDX and SMDXW (CRA has invested in this company) "SpectruMedix holds the exclusive worldwide rights to the 96 capillary electrophoresis DNA sequencing/genotyping technologies conceived at the Ames Research Laboratories and Funded by the Human Genome Program of the United States Department of Energy." spectrumedix.com SpectruMedix Corporation devotes substantially all of its resources to the development of high-speed DNA/gene sequencing instrumentation (the DNA Sequencer), an instrument for the acquisition, analysis and management of complex genetic information. The DNA Sequencer was developed in part from research efforts conducted at the United States Department of Energy and Ames Laboratories' Institute for Physical Research and Technology/Iowa State University biz.yahoo.com --- SMDX trades on the OTC BB and, like many of the developmental stage companies that trade there has tiny revenue,miniscule sales and shakey financials among a laundry list of potential hurdles What may set this company apart though is a deal with one of the genomics leaders. PE Corp (and its Celera Genomics CRA unit) have licensed SMDX patents. Further PE Corp/CRA has taken a stake in SMDX thru preferred shares and signed SMDX up to a consulting deal. Why doesn't the market know about this deal? Neither company has ever issued a press release on the licensing deal, stake or consulting deal. It is, however laid out in detail in SEC filings- tenkwizard.com. aug '99 Will SMDX move up if/when this deal becomes common knowledge? Impossible to say- but other companies involved with genomics (HYSQ, GLGC, CRGN et al)have seen their valuations rocket. SMDX has 3.66m shares out- 1.6m float and $3.26M in cash according to Yahoo biz.yahoo.com The stock started moving off its lows last week